Earnings summaries and quarterly performance for Sionna Therapeutics.
Executive leadership at Sionna Therapeutics.
Board of directors at Sionna Therapeutics.
BB
Bruce Booth
Detailed
Director
HE
H. Edward Fleming, Jr.
Detailed
Director
JV
Joanne Viney
Detailed
Director
JR
Joshua Resnick
Detailed
Director
LS
Laurie Stelzer
Detailed
Director
LI
Lucian Iancovici
Detailed
Director
MK
Marcella Kuhlmann Ruddy
Detailed
Director
PC
Paul Clancy
Detailed
Chairperson of the Board
PA
Peter A. Thompson
Detailed
Director
Research analysts covering Sionna Therapeutics.
Recent press releases and 8-K filings for SION.
Sionna Therapeutics Provides Update on Cystic Fibrosis Pipeline and Financial Position
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics is developing first-in-class NBD1 stabilizers to address the unmet need in cystic fibrosis (CF), a $12 billion market projected to grow to $15 billion+ by the end of 2030.
- The company's lead NBD1 stabilizers, SION-719 and SION-451, have both demonstrated positive Phase 1 data and are advancing to the next stages of development.
- SION-719 is currently in a Phase 2A proof-of-concept study in CF patients, with first patient data expected by mid-2026. This study aims for a 10 millimole sweat chloride improvement, which is considered clinically meaningful.
- SION-451 is serving as the anchor in a dual combination healthy volunteer study with complementary mechanisms, with data also anticipated in mid-2026.
- Sionna Therapeutics ended Q3 with $325 million in cash and has a cash runway into 2028, extending beyond these upcoming mid-2026 milestones.
2 days ago
Sionna Therapeutics Highlights Mid-2026 Data Readouts for CF Programs
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics is focused on developing first-in-class NBD1 stabilizers to address the unmet need in Cystic Fibrosis (CF), a $12 billion market projected to grow to over $15 billion by 2030.
- The company's lead NBD1 stabilizers, SION-719 and SION-451, have both shown positive Phase I data and are advancing in clinical development.
- Key catalysts include data readouts in mid-2026 for SION-719 from its Phase IIA Precision CF Study in CF patients, and for SION-451 from its healthy volunteer dual combination study.
- Sionna Therapeutics reported $325 million in cash at the end of Q3, providing a cash runway into 2028, which extends beyond these critical mid-2026 milestones.
2 days ago
Sionna Therapeutics Provides Pipeline and Financial Updates at J.P. Morgan Healthcare Conference
SION
Guidance Update
New Projects/Investments
- Sionna Therapeutics is developing first-in-class NBD1 stabilizers (SION-719 and SION-451) aimed at revolutionizing the treatment of Cystic Fibrosis (CF).
- The company anticipates releasing Phase 2A proof-of-concept data for SION-719 and healthy volunteer data for SION-451 dual combination in mid-2026.
- Sionna reported $325 million in cash at the end of Q3, providing a cash runway into 2028.
- The CF market is a $12 billion monopoly, projected to grow to over $15 billion by 2030, with a significant unmet need as two-thirds of patients on current standard of care do not achieve normal CFTR function.
2 days ago
Sionna Provides Update on Cystic Fibrosis Pipeline and Financial Position
SION
New Projects/Investments
Guidance Update
- Sionna is focused on transforming the standard of care in cystic fibrosis (CF) by targeting NBD1, with two primary compounds in development: SION-719 for an add-on strategy to Trikafta, and SION-451 as the anchor for a prioritized dual combination strategy.
- The company anticipates Phase 2a proof-of-concept data for SION-719 and data for the dual combination strategy with SION-451 in mid-2026.
- Sionna completed an IPO in February, raising $219 million, which provides a cash runway into 2028 and financial flexibility to execute its strategy.
- For SION-719, the company aims for at least a 10 millimole per liter change in sweat chloride, which is considered clinically meaningful and is projected to equate to approximately 3 points of FEV1.
- Sionna in-licensed three clinical-stage compounds from AbbVie, including galicaftor (2222), to expand its complementary mechanism strategy for dual combinations, with 2222 currently being evaluated in a Phase 1 healthy volunteer study in combination with 451.
Dec 4, 2025, 2:45 PM
Sionna Provides Update on Cystic Fibrosis Pipeline and Financial Position
SION
New Projects/Investments
Guidance Update
- Sionna is advancing two lead NBD1 stabilizer candidates for cystic fibrosis: SION-719 in a Phase 2a proof-of-concept study as an add-on to Trikafta, and SION-451 as the anchor for a prioritized dual combination strategy, with key data readouts for both programs expected in mid-2026.
- Following its February 2025 IPO that raised $219 million, Sionna has a cash runway into 2028, providing financial flexibility to execute its strategy and pursue its goal of achieving at least a 10 millimole per liter change in sweat chloride with SION-719.
- The company targets the $12 billion cystic fibrosis market, projected to grow to $15 billion, aiming to offer new, more effective options for patients.
Dec 4, 2025, 2:45 PM
Sionna Therapeutics reviews 2025 achievements and outlines 2026 clinical milestones
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics completed Phase 1 programs for its NBD1 stabilizers, SION-719 and SION-451, in 2025, reporting positive data for both compounds.
- The company initiated a Phase 2 proof-of-concept study for SION-719 as an add-on to Trikafta and a healthy volunteer Phase 1 study for SION-451 in a dual combination with other modulators, with data for both studies anticipated in mid-2026.
- Sionna completed an IPO in February 2025, raising over $219 million in gross proceeds, which provides a cash runway into 2028.
- The company's strategy focuses on improving CFTR function and normalizing sweat chloride levels, with a preferred dual combination approach, believing their NBD1 mechanism offers differentiated efficacy compared to existing treatments.
Dec 3, 2025, 5:30 PM
Sionna Therapeutics reviews 2025 accomplishments and outlines 2026 clinical milestones
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics completed Phase 1 programs for its two NBD1 stabilizers, SION-719 and SION-451, in 2025, reporting positive data.
- The company initiated a Phase 2 proof-of-concept study for SION-719 as an add-on to Trikafta and a healthy volunteer Phase 1 study for SION-451 in a dual combination, with data from both expected in mid-2026.
- Sionna completed an IPO in February 2025, raising over $219 million in gross proceeds, which provides a cash runway into 2028.
- The company aims to address the unmet need in cystic fibrosis by driving more patients to normal CFTR function, noting that two-thirds of patients on current standard-of-care treatments do not achieve normal levels.
- Sionna expresses high confidence in its CFHBE assay, which has been validated by matching results with published clinical data for Vertex compounds, supporting its differentiated NBD1 mechanism.
Dec 3, 2025, 5:30 PM
Sionna Therapeutics Highlights 2025 Accomplishments and 2026 Clinical Milestones
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics completed Phase I programs for its two NBD1 stabilizers, SION-719 and SION-451, in 2025 with positive data.
- The company initiated a Phase II proof-of-concept study for SION-719 (Precision CF study) and a healthy volunteer Phase I study for SION-451 in combination with other modulators, with data for both expected in mid-2026.
- Sionna completed an IPO in February 2025, raising over $219 million gross proceeds, which provides a cash runway into 2028.
- The company's strategy involves advancing SION-719 as an add-on to Trikafta and SION-451 as the anchor for a preferred dual combination approach, aiming to improve CFTR function and normalize sweat chloride levels, with the SION-719 Phase II study powered for at least a 10 mmol/L change in sweat chloride.
Dec 3, 2025, 5:30 PM
Sionna Provides Updates on Cystic Fibrosis Programs and Cash Runway
SION
New Projects/Investments
Guidance Update
- Sionna is advancing two NBD1 stabilizers for cystic fibrosis: 719 is in a Phase 2a proof-of-concept study (PreciSION CF study) with data expected by mid-2026.
- A healthy volunteer dual combination study for 451 with two different correctors (Sion-2222 and Sion-109) has also started, with data anticipated by mid-2026.
- The company targets at least a 10-millimole sweat chloride reduction in the Phase 2a study, a clinically meaningful bar that could translate to three percentage points of FEV1 improvement.
- Sionna reported $325 million in cash at the start of Q3, extending its cash runway into 2028, well past the mid-2026 data readouts.
Nov 12, 2025, 1:00 PM
Sionna Therapeutics Provides Clinical Development and Financial Updates
SION
New Projects/Investments
Guidance Update
- Sionna Therapeutics is developing two NBD1 stabilizers, 719 and 451, for cystic fibrosis, aiming to transform the standard of care.
- The Phase 2a PreciSION CF study for 719, an add-on to Trikafta, is targeting at least a 10-millimole sweat chloride reduction, with data expected in mid-2026.
- A healthy volunteer dual combination study for 451 with either Sion-2222 or Sion-109 is also underway, with data anticipated by mid-2026.
- Sionna reported a cash balance of $325 million at the start of Q3, providing a cash runway into 2028, extending beyond the mid-2026 data readouts.
Nov 12, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more